77 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
13 May 24
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
7:15am
release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation … in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts
8-K
EX-99.1
TRML
Tourmaline Bio Inc
19 Mar 24
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:09am
not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 … process; unexpected litigation or other disputes; the impacts of macroeconomic conditions Tourmaline’s business, clinical trials and financial position
8-K
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended
8-K
EX-1.1
53ly2w
26 Jan 24
Other Events
4:12pm
8-K
EX-99.1
b8vuvn7zv 0c
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
r2qakc92ahryll7uqxi
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
EX-99.1
1vdlrc3yl3 3qo
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
EX-99.2
c7ctz8 ug2c
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
EX-99.1
1wn skicpubxf
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
8-K
EX-99.1
37wmwy6yei07i5gcuyl
14 Nov 23
Index to Unaudited Condensed Financial Statements
5:15pm
8-K
EX-99.1
5psjrac
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
te1663koo8q4di
17 Oct 23
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
6:35pm
8-K
EX-99.1
pgwqfszi5h7k 44q
17 Oct 23
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
6:35pm
425
llow7hjo0t40ym1jjkbu
10 Oct 23
Business combination disclosure
4:32pm
8-K/A
7bd2w7ucqx0ntba 9yw
10 Oct 23
Other Events
4:30pm
425
kmyiqq0lz 5i3wj
10 Oct 23
Business combination disclosure
12:00am
8-K
ri5uu ryx2
6 Oct 23
Talaris Therapeutics Declares Special Dividend
5:30pm